Novavax jumps as human testing begins on coronavirus vaccine

Share

The vaccine induced a strong immune response, generated neutralizing antibodies, and decreased viral infection in the upper respiratory tract to nearly undetectable levels.

Novavax received its largest ever investment of $388 million from the Coalition for Epidemic Preparedness and Innovations (CEPI), which was co-founded and set up in November 2017 with funding from the Bill and Melinda Gates Foundation.

Most of the vaccines presently on the experimental stage are created to coach the immune system to recognise the "spike" protein that studs the coronavirus' outer floor, priming the physique to react as if it have been uncovered to the true virus.

The testing will mark the first human trial of a COVID-19 vaccine in the Southern Hemisphere and will take place at Melbourne's Alfred Hospital.

Australia's largest Phase 1 Clinical trials specialist, Nucleus Network, has today commenced dosing the first human participants for the Phase 1/2 trial of NVX-CoV2373, a SARS-CoV-2 Recombinant Spike Protein Nanoparticle vaccine, at its Melbourne clinic.

National Vaccine Institute director, Nakorn Premsri said if the trials show promising results, the vaccine would be tested on humans by end of this year or early next year.

The four groups will be provided with the WHO's requirements for Covid-19 vaccine target product profiles; pre-qualification process for World Health Organization approvals; and the FDA's updated guidelines on clinical trials.

New COVID-19 Case in Mason County
Tune into NewsWatch 12 at 5:00 and 6:00 p.m. tonight for the most up to date Coronavirus numbers and information. The county marked the first death attributed to the virus in southern OR on April 11, an 81-year-old man.

"The way we make a vaccine is we never touch the virus", Novavax told The Associated Press last month.

"The development of a safe and effective vaccine is a crucial tool in the control of COVID-19 world-wide and a global effort is well underway to develop and test various vaccine candidates", says David Clark.

A mid-stage trial of the vaccine is already underway in Wuhan, Reuters reports.

The trial in China assessed the safety of the vaccine in humans, and its ability to generate an immune response in 108 healthy adults who did not have SARS-CoV-2 infection.

The first phase of the clinical trial will be randomized, observer-blinded, and placebo-controlled, Novavax said. Preliminary immunogenicity and safety results from the Phase 1 portion of the trial are expected in July 2020. Novavax used genetic engineering to grow harmless copies of the coronavirus spike protein in giant vats of insect cells in a laboratory.

Novavax, Inc. (Nasdaq:NVAX), is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases and address urgent, global health needs. The biotech anticipates providing a first look in July at what sort of immune responses are generated.

Thai researchers will inject the vaccine in low doses into five monkeys, and five more will receive the vaccine in higher doses.

Share